Gemtor 1 gm (Gemcitabine) Injection – A Powerful Ally in Cancer Treatment
Gemtor 1 gm Injection, containing the active ingredient Gemcitabine, is a widely used chemotherapy medication designed for the treatment of various cancers including ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. This life-saving drug is manufactured by Eskayef Pharmaceuticals Ltd., one of the most prestigious pharmaceutical manufacturers in Bangladesh. It is professionally supplied by Saif Pharma, a leading global distributor of oncology medicines.
What is Gemtor (Gemcitabine) and How Does it Work?
Gemcitabine, the active compound in Gemtor, is an antimetabolite chemotherapy agent. It works by targeting cancer cells during DNA synthesis. Once inside the body, Gemcitabine is metabolized into two active forms – dFdCDP and dFdCTP. These forms interfere with DNA replication by:
Inhibiting ribonucleotide reductase, reducing the availability of deoxynucleotides necessary for DNA synthesis.
Competing with deoxycytidine triphosphate (dCTP) for incorporation into DNA.
Causing chain termination after one nucleotide is added post-Gemcitabine incorporation.
This leads to apoptotic cell death, effectively stopping the growth and spread of cancer cells.
Therapeutic Indications of Gemtor 1 gm Injection
Gemtor 1 gm is approved for use in various types of cancer, either as monotherapy or in combination with other agents:
Ovarian Cancer
Gemcitabine is used in combination with carboplatin for the treatment of advanced ovarian cancer in patients who have relapsed at least six months after completing platinum-based therapy.
Breast Cancer
Used alongside paclitaxel, Gemtor is effective as a first-line treatment for metastatic breast cancer, especially in cases where anthracycline-based regimens have failed or are contraindicated.
Non-Small Cell Lung Cancer (NSCLC)
Gemcitabine, in combination with cisplatin, is used for the treatment of locally advanced or metastatic NSCLC, offering a significant extension in survival and symptom control.
Pancreatic Cancer
Gemcitabine is a go-to single-agent chemotherapy for patients with locally advanced or metastatic pancreatic cancer, helping to improve overall survival and reduce disease progression.
Dosage & Administration
Gemtor 1 gm Injection is administered intravenously by a healthcare professional. Dosage is determined based on body surface area (BSA) and specific cancer type.
Ovarian Cancer: 1000 mg/m² IV over 30 minutes on Days 1 and 8 every 21 days.
Breast Cancer: 1250 mg/m² IV over 30 minutes on Days 1 and 8 every 21 days.
NSCLC: 1000 mg/m² IV on Days 1, 8, and 15 of a 28-day cycle or 1250 mg/m² on Days 1 and 8 of a 21-day cycle.
Pancreatic Cancer: 1000 mg/m² IV weekly for 7 weeks, followed by a one-week rest, then once weekly for 3 weeks per 28-day cycle.
Note: Dosing may be modified based on blood counts and organ function.
Side Effects of Gemtor (Gemcitabine)
Like most chemotherapy agents, Gemtor may cause several side effects, which should be monitored by healthcare professionals:
Common Side Effects:
Nausea, vomiting
Fever
Fatigue
Rash
Edema
Hematologic Effects:
Anemia
Neutropenia
Thrombocytopenia
Hepatic & Renal:
Elevated liver enzymes
Proteinuria
Hematuria
Respiratory:
Dyspnea
Pulmonary toxicity (rare but serious)
Immediate medical attention is required if shortness of breath, severe fever, or unusual bleeding occurs.
Warnings & Precautions
Infusion Time: Should not exceed 60 minutes to reduce the risk of toxicity.
Myelosuppression: Monitor CBC counts before each treatment cycle.
Pulmonary Toxicity: Discontinue Gemcitabine if severe lung toxicity is observed.
Renal Monitoring: Check renal function to avoid Hemolytic-Uremic Syndrome (HUS).
Pregnancy Category D: Should not be used during pregnancy or lactation unless absolutely necessary.
Use in Pregnancy and Lactation
Gemcitabine is teratogenic and poses a significant risk to the fetus. Women of reproductive age should use effective contraception during treatment. Lactating mothers should discontinue breastfeeding or the drug due to potential toxicity to infants.
Storage & Handling Instructions
Store below 30°C
Protect from light and moisture
Keep out of reach of children
For intravenous use only by trained medical personnel
Manufacturer Information
Eskayef Pharmaceuticals Ltd. is a premier pharmaceutical company based in Bangladesh, known for manufacturing world-class medicines with a commitment to quality, compliance, and patient care. Originating from the Bangladesh operation of SK&F USA, Eskayef has built a legacy of trust and innovation in healthcare.
Learn more: www.skfbd.com
Global Supplier: Saif Pharma
Saif Pharma, established in 2014, is a trusted name in the global distribution of oncology medicines, serving clients in over 60 countries, including the United States, Canada, Saudi Arabia, UAE, India, Pakistan, and China. Our mission is to ensure affordable access to top-quality cancer treatments for all.
Visit us: www.saifpharma.com
Why Choose Gemtor 1 gm from Saif Pharma?
WHO-GMP certified manufacturer (Eskayef)
Reliable global supplier with decades of experience
Competitive pricing with quality assurance
Fast delivery and professional customer support
Trusted by hospitals, clinics, and pharmacies worldwide
Final Words
Gemtor 1 gm (Gemcitabine) Injection is a trusted chemotherapy agent used globally in the treatment of major cancers. With the combined excellence of Eskayef Pharmaceuticals and Saif Pharma, this product ensures effective, affordable, and accessible cancer care to those who need it most. Whether you are a hospital, clinic, or pharmacy sourcing high-quality oncology medications, Gemtor is a solution you can depend on
